Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Dicerna Pharmaceuticals Inc.
DescriptionExtended Dicer substrate short interfering RNA (siRNA) targeting beta-catenin (CTNNB1) delivered using Dicerna's EnCore lipid nanoparticle technology
Molecular Target Beta-catenin (CTNNB1)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today